NCT06631040
Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL
StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Incidence of dose-limiting toxicity (DLTs)
Timeframe: 4 weeks
Assessment of Maximum Tolerated Dose (MTD)
Timeframe: 4 weeks
Overall Remission Rate (ORR)
Timeframe: 8 weeks
Secondary (2)
Progression-free survival (PFS)
Duration of Response (DOR)
Arms and interventions
Acute lymphocytic leukemia, in relapseExperimental
Biologicals: anti CD19 CAR NK cells
Sites
1 site in 1 country
- Shahid Ghazi Hospital, Tabriz university of medical sciencesTabriz, Iran